RNF149 Knockout HEK293 Cell Line
Cat.No.:
EDJ-KQ15102
Species:
Human
Cell Name:
HEK293
Gene:
RNF149
Gene ID:
284996
Size:
1×10⁶cells
RNF149 Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDJ-KQ15102 |
|---|---|
| Product Name | RNF149 Knockout Cell Line (HEK293) |
| Cell Line | HEK293 |
| Cellosaurus ID | CVCL_0045 |
| Cell Line Synonyms | Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293 |
| Gene | |
| NCBI Gene ID | |
| Gene Synonyms | DNAPTP2 |
| Summary |
Predicted to enable ubiquitin protein ligase activity. Predicted to be involved in ubiquitin-dependent protein catabolic process. Predicted to act upstream of or within cellular response to xenobiotic stimulus; negative regulation of MAPK cascade; and regulation of protein stability. Located in membrane. [provided by Alliance of Genome Resources, Jul 2025]
|
| Associated Diseases | Non-tumor |
| Morphology | Adherent |
| Passage Ratio | 1/5,2days |
| Complete Culture Medium | DMEM + 10% FBS |
| Freezing Medium | 95% Complete culture medium+ 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HEK293 | STR Info (Cell bank) Cell Line: HEK293 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1P0 | 12 | 11 | 12 | |
| D2S1338 | 19 | 19 | ||
| D3S1358 | 15 | 17 | 15 | 17 |
| D5S818 | 8 | 8 | 9 | |
| D7S820 | 11 | 12 | 11 | 12 |
| D8S1179 | 12 | 14 | 12 | 14 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 13 | 9 | 13 |
| D18S51 | 17 | 18 | 17 | 18 |
| D19S433 | 15 | 18 | 15 | 18 |
| D21S11 | 28 | 30.2 | 28 | 30.2 |
| FGA | 23 | 23 | ||
| Penta D | 9 | 10 | 9 | 10 |
| Penta E | 7 | 15 | 7 | 15 |
| TH01 | 7 | 9.3 | 7 | 9.3 |
| TPOX | 11 | 11 | ||
| vWA | 16 | 19 | 16 | 19 |
| D6S1043 | 11 | 11 | ||
| D12S391 | 19 | 21 | 11 | 15 |
| D2S441 | 11 | 15 | 11 | 15 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
Research Publications
Encephalomyocarditis virus evades IFN-mediated antiviral response by RNF149 targeting JAK1 for ubiquitination and degradation.
IF=5.4
Virulence
Encephalomyocarditis virus (EMCV), an important zoonotic pathogen, causes an acute disease characterized primarily by encephalitis and myocarditis. Interferon (IFN) activates the JAK-STAT signaling pathway to induce the expression of interferon-stimulated genes (ISGs), resulting in antiviral effects. However, the mechanism through which EMCV evades the immune system via the IFN-mediated JAK-STAT signaling pathway remains poorly understood. Here, we identified an E3 ubiquitin ligase, RNF149, that is upregulated in EMCV-infected cells. Overexpression of RNF149 inhibited type I IFN-mediated JAK-STAT signaling pathway activation and its antiviral response, enhancing viral replication. Knockout of RNF149 promoted ISGs expression. Notably, RNF149 interacted with JAK1 and downregulated its protein expression through the E3 ubiquitin ligase. RNF149 promoted the K27- and K33-linked ubiquitination of JAK1, which promoted JAK1 degradation through the proteasome pathway. Taken together, these data describe a negative regulatory mechanism involving RNF149 in interferon antiviral activity and provide insights into the mechanism by which EMCV evades host antiviral immunity. These results provide a new strategy for treating viral infections.
This KO model may be useful for:
- Investigating the role of RNF149 in JAK1-mediated IFN signaling and antiviral immunity
- Studying ubiquitination and degradation mechanisms of JAK family kinases
- Evaluating host-pathogen interactions, particularly for encephalomyocarditis virus (EMCV)
- Screening antiviral compounds targeting the RNF149-JAK1 axis
- Functional validation of RNF149 substrates in innate immune pathways